What Manufacturers Need to Know
Seventeen revised draft product-specific guidance documents reflect FDA’s evolving scientific and regulatory approach to generic peptide drug development.
On July 28, 2026, the U.S. Food and Drug Administration (FDA) published 17 revised draft product-specific guidances (PSGs) addressing the development of generic peptide drugs, including products used to treat diabetes, obesity, osteoporosis, and macular degeneration.
The revisions reflect advances in analytical science, manufacturing technology, and regulatory experience with complex peptide products. They also provide updated recommendations for manufacturers seeking approval through the abbreviated new drug application (ANDA) pathway.
Unlike many conventional small-molecule drugs, peptide products can present additional challenges involving molecular structure, manufacturing-related impurities, and biological activity. These characteristics can complicate the demonstration that a proposed generic product is equivalent to its reference listed drug.
FDA’s revised guidances address five important areas of generic peptide development.
Five Areas of Regulatory Focus
Peptide Manufacturing and ANDA Eligibility
The revised guidances address the submission of ANDAs for peptides manufactured using recombinant, synthetic, or semisynthetic production methods. These recommendations are particularly relevant when the proposed generic and reference products are manufactured using different technologies.
Innate Immune Response Testing
Peptide products may present immunological concerns that require evaluation. FDA’s updated recommendations address testing related to innate immune responses, an important consideration when assessing product quality and potential safety risks.
Impurity Thresholds
Peptide manufacturing can produce impurities that differ depending on the manufacturing process. The revised guidance documents address impurity thresholds, providing recommendations relevant to impurity characterization, evaluation, and control during generic product development.
Higher-Order Structure Assessment
The three-dimensional structure of a peptide can influence its biological properties. FDA’s recommendations address higher-order structure assessment as part of the scientific evaluation of certain generic peptide products.
Biological Activity Assessment
Demonstrating appropriate biological activity is another important consideration in evaluating peptide products. The revised guidances address biological activity assessments that may contribute to demonstrating equivalence between proposed generic products and their reference drugs.
Together, these five areas illustrate FDA’s emphasis on scientific characterization and evidence-based assessment of complex peptide products. The specific recommendations and supporting evidence will depend on the individual product and its applicable guidance.
FDA Withdraws Earlier Peptide Guidance
Alongside the revised PSGs, FDA withdrew its May 2021 guidance, ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, stating that it no longer reflects the agency’s current scientific thinking.
FDA also indicated plans to revise that guidance in 2026.
The withdrawal is particularly relevant for manufacturers whose development strategies relied on the earlier recommendations. Those manufacturers should review the updated product-specific guidance and evaluate whether changes to their development or submission strategies are appropriate.
Implications for Generic Peptide Developers
The revised draft guidances provide an opportunity for manufacturers to reassess their analytical, manufacturing, and regulatory strategies before submitting an ANDA.
Manufacturers developing affected peptide products should consider whether their existing programs adequately address the applicable recommendations for impurity characterization, structural assessment, biological activity, and immunological evaluation.
The recommendations may also have implications beyond the 17 products specifically identified. FDA encourages developers of other generic peptide products to consult its Office of Generic Drugs through formal meetings or controlled correspondence when these recommendations may be applicable.
Importantly, the revised guidances remain in draft form. Manufacturers should distinguish FDA’s proposed recommendations from finalized guidance and applicable regulatory requirements when making development decisions.
Products Covered by the Revised Draft Guidances
The 17 revised draft PSGs address nine peptide ingredients, several of which have multiple reference listed products.
|
Peptide ingredient |
Reference products |
|
Calcitonin salmon |
Calcimar, Miacalcin |
|
Dasiglucagon hydrochloride |
Zegalogue |
|
Glucagon |
Baqsimi, Glucagon, Gvoke |
|
Liraglutide |
Victoza, Saxenda |
|
Pegcetacoplan |
Syfovre, Empaveli |
|
Semaglutide |
Ozempic, Wegovy |
|
Teriparatide |
Forteo, Teriparatide |
|
Tirzepatide |
Mounjaro, Zepbound |
|
Vosoritide |
Voxzogo |
Manufacturers can review the individual recommendations through FDA’s Product-Specific Guidance Database.
Looking Ahead
FDA’s latest revisions underscore the increasing importance of advanced analytical methods and product-specific scientific evidence in generic peptide development.
For manufacturers, the central consideration is not simply whether a peptide can be produced using a particular manufacturing method, but whether the proposed generic product can be adequately characterized and demonstrated to meet applicable requirements for quality, safety, and effectiveness.
As FDA continues refining its approach to complex generic products, manufacturers that evaluate these expectations early in development will be better positioned to identify regulatory gaps, plan appropriate studies, and prepare scientifically supported submissions.
FDA Grants Accelerated Approval to Tarlatamab-dlle
Treatment for lung cancer with progression following platinum-based chemotherapy On May 16, 2024, the Food and Drug Administration (FDA) granted accelerated approval to Imdelltra (tarlatamab-dlle) manufactured by Amgen, Inc. for the treatment of extensive stage small...
FDA Approves New Imaging Drug Lumisight
A Significant Improvement for Surgical Oncology The U.S. Food and Drug Administration (FDA) has granted approval to LumiSight (pegulicianine) for use in adults undergoing breast lumpectomy, marking a significant advancement in surgical oncology. Lumisight, a...
FDA Approves Xolremdi for WHIM Syndrome
A Breakthrough for Rare Infections In a groundbreaking development, the U.S. Food and Drug Administration (FDA) has granted approval for Xolremdi (mavorixafor) capsules, marking a significant milestone in the treatment of WHIM syndrome. Let's delve into what this...
Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer
Product Approval for Cervical Cancer Drug Exciting news emerged from the U.S. Food and Drug Administration (FDA) on April 29, 2024, as traditional approval was granted to tisotumab vedotin-tftv, marketed as Tivdak by Seagen Inc. (now a part of Pfizer Inc.). This...
FDA Approves Anktiva for Bladder Cancer
New Drug Approval In a significant development for patients battling BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), the Food and Drug Administration (FDA) has granted approval to nogapendekin alfa inbakicept-pmln, marketed as Anktiva by Altor...
FDA Approves Versatile Antibiotic Zevtera for Three Key Infections
FDA Approves Versatile Antibiotic Zevtera for Three Key Infections The U.S. Food and Drug Administration (FDA) announced today that the fight against bacterial infections has gained a significant boost with the recent approval of Zevtera (ceftobiprole medocaril sodium...
FDA Approves Treatment for Platinum-Resistant Ovarian Cancer
In a significant development for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, on March 22, 2024 the Food and Drug Administration (FDA) granted approval for mirvetuximab soravtansine-gynx, marketed as Elahere by...
FDA Approves Lamzede for Treatment of Alpha-mannosidosis
The U.S. Food and Drug Administration (FDA) on February 17, 2023 announced the approval the first-ever enzyme replacement therapy (ERT) for the treatment of rare alpha-mannosidosis, a genetic disorder that affects an individual's ability to break down complex sugars....
FDA Approves Rukabia for HIV Treatment
The U.S. Food and Drug Administration (FDA) on December 22, 2022 announced the approval of a new HIV drug called Rukobia (fostemsavir) for adults living with HIV who have limited treatment options. This drug is the first in a new class of HIV medications known as...
FDA Accelerated Approval for Alzheimer’s Disease Treatment
The US Food and Drug Administration (FDA) announced on 06 January, 2023 that it had granted accelerated approval for the Alzheimer's disease treatment Leqembi. This is a significant milestone in the fight against Alzheimer's, a debilitating and progressive brain...




